PTC治療 PTCT 深 滬
已收盤 09-05 16:00:00 美东时间
57.26
-0.750
-1.29%
華盛通- 最 高58.73
- 今 開58.61
- 成交量 151.71万股
- 最 低 57.08
- 昨 收 58.01
- 總市值 45.49亿
- 52周最高 58.73
- 市盈率 靜 --
- 換手率 1.91%
- 52周最低 33.575
- 委 比 -86.06%
- 總股本 7943.81万
- 歷史最高 78.72
- 量 比 1.08
- 振 幅 2.84%
- 歷史最低 4.03
- 每 手 1
- 風險率 5.60%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Cantor Fitzgerald Reiterates Overweight on PTC Therapeutics, Maintains $118 Price Target
Cantor Fitzgerald analyst Kristen Kluska reiterates PTC Therapeutics (NASDAQ:PTCT) with a Overweight and maintains $118 price target.
09-03 21:49
美股大行评级 | 潜在涨幅166.67%！美银证券上调Rocket Pharmaceuticals目标价至10美元，评级升至"买入"
今日重点评级关注：美银证券：上调Rocket Pharmaceuticals评级至"买入"，目标价从4美元升至10美元；花旗：维持小鹏汽车"买入"评级，目标价从29美元升至29.4美元
08-21 19:00
B of A Securities Maintains Buy on PTC Therapeutics, Lowers Price Target to $76
B of A Securities analyst Tazeen Ahmad maintains PTC Therapeutics (NASDAQ:PTCT) with a Buy and lowers the price target from $82 to $76.
08-20 20:21
PTC Therapeutics rare disease therapy rejected by FDA
PTC Therapeutics (NASDAQ:PTCT) announced on Tuesday that the U.S. FDA issued a complete response letter in response to its marketing application for vatiquinone, rejecting the small molecule drug as a...
08-19 20:42
PTC Therapeutics Receives FDA Complete Response Letter
PTC Therapeutics ( ($PTCT) ) has issued an update. On August 19, 2025, PTC Ther...
08-19 20:28
PTC Therapeutics’ Earnings Call Highlights Sephience Success
PTC Therapeutics (($PTCT)) has held its Q2 earnings call. Read on for the main ...
08-13 08:21
Leerink Partners Issues a Hold Rating on PTC Therapeutics (PTCT)
Leerink Partners analyst Joseph Schwartz assigned a Hold rating to PTC Therapeu...
08-12 16:26
美股大行评级 | 潜在涨幅286.44%！RBC Capital上调Edgewise Therapeutics目标价至49美元，维持"跑赢大市"评级
今日重点评级关注：RBC Capital：维持Edgewise Therapeutics"跑赢大市"评级，目标价从48美元升至49美元；RBC Capital：维持Nuvation Bio"跑赢大市"评级，目标价从6美元升至7美元
08-11 09:43
PTC Therapeutics outlines Sephience $1B-plus U.S. revenue potential following FDA and EU launches
Earnings Call Insights: PTC Therapeutics (PTCT) Q2 2025 Management View CEO Matthew B. Klein opened the call highlighting the "first approvals for Sephience for the treatment of children and adults wi...
08-09 03:19
Wells Fargo Maintains Overweight on PTC Therapeutics, Raises Price Target to $79
Wells Fargo analyst Tiago Fauth maintains PTC Therapeutics (NASDAQ:PTCT) with a Overweight and raises the price target from $78 to $79.
08-08 23:26
